PIK3CA alterations in Middle Eastern ovarian cancers

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Abubaker, Jehad ^a   Bavi, Prashant ^a   Al Haqawi, Wael ^a   Jehan, Zeenath ^a   Munkarah, Adnan ^a   Uddin, Shahab ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; K RAS PROTEIN; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; SERINE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; RAS PROTEIN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CARCINOGENESIS; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVITY; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE EAST; OVARY CARCINOMA; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; AGED; BIOSYNTHESIS; ENZYMOLOGY; GENE DOSAGE; GENE SILENCING; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OVARY TUMOR; SAUDI ARABIA; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; SAUDI ARABIA; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 68949212362     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-51     Document Type: Article

References (46)

1. Fishman DA Bozorgi K The scientific basis of early detection of epithelial ovarian cancer: The national ovarian cancer early detection program (NOCEDP) Cancer Treatment and Research: Ovarian Cancer Boston: Kluwer Academic Publishers Stack MS, Fishman DA 2001, 3:28.
2. Fader AN Rose PG Role of surgery in ovarian carcinoma J Clin Oncol 2007, 25:2873-2883. 10.1200/JCO.2007.11.0932 17617518
3. Khoja TA The Five-Year Cancer Incidence, 1998-2002 Report Gulf centre for cancer registration 2006, 41-43.
4. Cannistra SA Medical progress: Cancer of the ovary New England Journal of Medicine 2004, 351:2519-2529. 10.1056/NEJMra041842 15590954
5. Jemal A Tiwari RC Murray T Ghafoor A Samuels A Ward E Feuer EJ Thun MJ American Cancer Society. Cancer statistics CA Cancer J Clin 2004, 54:8-29. 10.3322/canjclin.54.1.8 14974761
6. Barda G Menczer J Chetrit A Lubin F Beck D Piura B Glezerman M Modan B Sadetzki S Comparison between primary peritoneal and epithelial ovarian carcinoma: A population-based study Am J Obstet Gynecol 2004, 190:1039-45. 10.1016/j.ajog.2003.09.073 15118638
7. Cantley LC The phosphoinositide 3-kinase pathway Science 2002, 296:1655-1657. 10.1126/science.296.5573.1655 12040186
8. Vivanco I Sawyers CL The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2002, 2:489-501. 10.1038/nrc839 12094235
9. Shayesteh L Lu Y Kuo WL Baldocchi R Godfrey T Collins C Pinkel D Powell B Mills GB Gray JW PIK3CA is implicated as an oncogene in ovarian cancer Nat Genet 1999, 21:99-102. 10.1038/5042 9916799
10. Willner J Wurz K Allison KH Galic V Garcia RL Goff BA Swisher EM Alternate molecular genetic pathways in ovarian carcinomas of common histological types Hum Pathol 2007, 38:607-13. 10.1016/ j.humpath.2006.10.007 17258789
11. Campbell IG Russell SE Choong DY Montgomery KG Ciavarella ML Hooi CS Cristiano BE Pearson RB Phillips WA Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res 2004, 64:7678-81. 10.1158/ 0008-5472.CAN-04-2933 15520168
12. Zhang L Huang J Yang N Greshock J Liang S Hasegawa K Giannakakis A Poulos N O'Brien-Jenkins A Katsaros D Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer Clin Cancer Res 2007, 13:5314-21. 10.1158/1078-0432.CCR-06-2660 17875760
13. Woenckhaus J Steger K Sturm K Münstedt K Franke FE Fenic I Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer Virchows Arch 2007, 450:387-95. 10.1007/s00428-006-0358-3 17377809
14. Kodaki T Woscholski R Hallberg B Rodriguez-Viciana P Downward J Parker PJ Phosphatidylinositol-3-OH kinase as a direct target of KRAS Nature 1994, 370:527-32. 10.1038/370527a0 8052307
15. Xing M BRAF mutation in thyroid cancer Endocr Relat Cancer 2005, 12:245-62. 10.1677/erc.1.0978 15947100
16. Singer G Oldt R 3rd Cohen Y Wang BG Sidransky D Kurman RJ Shihe M Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma JNCI 2003, 95:484-486. 12644542
17. Sieben NL Macropoulos P Roemen GM Kolkman-Uljee SM Jan Fleuren G Houmadi R Diss T Warren B Al Adnani M De Goeij AP Krausz T Flanagan AM In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours J Pathol 2004, 202:336-340. 10.1002/path.1521 14991899
18. Bavi P Jehan Z Atizado V Al-Dossari H Al-Dayel F Tulbah A Amr SS Sheikh SS Ezzat A El-Solh H Uddin S Al-Kuraya K Prevalence of fragile histidine triad expression in tumors from saudi arabia: A tissue microarray analysis Cancer Epidemiol Biomarkers Prev 2006, 15:1708-1718. 10.1158/ 1055-9965.EPI-05-0972 16985034
19. Kononen J Bubendorf L Kallioniemi A Bärlund M Schraml P Leighton S Torhorst J Mihatsch MJ Sauter G Kallioniemi OP Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 1998, 4:844-847. 10.1038/nm0798-844 9662379
20. Russel P Surface epithelial-stromal tumors of the ovary Blaustein's Pathology of the Female Genital Tract New York: Springer-Verlag Kurman RJ 1995, 705-782.
21. Abubaker J Jehan Z Bavi P Sultana M Al-Harbi S Ibrahim M Al-Nuaim A Ahmed M Amin T Al-Fehaily M Al-Sanea O Al-Dayel F Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population J Clin Endocrinol Metab 2008, 93:611-8. 10.1210/ jc.2007-1717 18000091
22. Abubaker J Bavi PP Al-Harbi S Siraj AK Al-Dayel F Uddin S Al-Kuraya K PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma Leukemia 2007, 21:2368-70. 10.1038/sj.leu.2404873 17657213
23. Saal LH Holm K Maurer M Memeo L Su T Wang X Yu JS Malmström PO Mansukhani M Enoksson J Hibshoosh H Borg A PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma Cancer Res 2005, 65:2554-2559. 10.1158/0008-5472-CAN-04-3913 15805248
24. Bavi PP Abubaker JA Jehan ZD Al-Jomah NA Siraj AK Al-Harbi SR Atizado VL Abduljabbar AS Alhomoud SJ Ashari LH Al-Dayel FH Uddin S Colorectal carcinomas from Middle East. Molecular and tissue microarray analysis of genomic instability pathways Saudi Med J 2008, 29:75-80. 18176677
25. Uddin S Hussain AR Siraj AK Manogaran PS Al-Jomah NA Moorji A Atizado V Al-Dayel F Belgaumi A El-Solh H Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival Blood 2006, 108:4178-86. 10.1182/blood-2006-04-016907 16946303
26. Uddin S Siraj AK Al-KRASheed M Ahmed M Bu R Myers JN Al-Nuaim A Al-Sobhi S Al-Dayel F Bavi P Hussain AR Al-Kuraya KS Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers J Clin Endocrinol Metab 2008, 93:4088-4097. 10.1210/jc.2008-0503 18682509
27. Camp RL Dolled-Filhart M Rimm DL X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization Clin Cancer Res 2004, 10:7252-7259. 10.1158/1078-0432.CCR-04-0713 15534099
28. Pfaffl MW Horgan GW Dempfle L Relative expression software tool (REST(C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCR Nucl Acids Res 2002, 30:e36. 113859 11972351 10.1093/nar/30.9.e36
29. Samuels Y Diaz LA Jr Schmidt-Kittler O Cummins JM Delong L Cheong I Rago C Huso DL Lengauer C Kinzler KW Vogelstein B Velculescu VE Mutant PIK3CA promotes cell growth and invasion of human cancer cells Cancer Cell 2005, 7:561-73. 10.1016/j.ccr.2005.05.014 15950905
30. Wang Y Helland A Holm R Kristensen GB Børresen-Dale AL PIK3CA mutations in advanced ovarian carcinomas Hum Mutat 2005, 25:322. 10.1002/ humu.9316 15712344
31. Levine DA Bogomolniy F Yee CJ Lash A Barakat RR Borgen PI Boyd J requent mutation of the PIK3CA gene in ovarian and breast cancers Clin Cancer Res 2005, 11:F2875-8. 10.1158/1078-0432.CCR-04-2142
32. Qiao YH Cheng J Guo RX Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer Zhonghua Fu Chan Ke Za Zhi 2007, 42:325-9. 17673045
33. Nakayama K Nakayama N Kurman RJ Cope L Pohl G Samuels Y Velculescu VE Wang TL Shih IeM Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms Cancer Biol Ther 2006, 5:779-85. 16721043
34. Kurose K Zhou XP Araki T Cannistra SA Maher ER Eng C Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas Am J Pathol 2001, 158:2097-106. 1891985 11395387
35. Cully M You H Levine AJ Mak TW Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis Nat Rev Cancer 2006, 6:184-92. 10.1038/nrc1819 16453012
36. Wang HQ Altomare DA Skele KL Poulikakos PI Kuhajda FP Di Cristofano A Testa JR Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells Oncogene 2005, 24:3574-82. 10.1038/sj.onc.1208463 15806173
37. Astanehe A Arenillas D Wasserman WW Leung PC Dunn SE Davies BR Mills GB Auersperg N Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer J Cell Sci 2008, 121:664-74. 10.1242/jcs.013029 18270270
38. Maruyama N Miyoshi Y Taguchi T Tamaki Y Monden M Noguchi S Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women Clin Cancer Res 2007, 13:408-414. 10.1158/ 1078-0432.CCR-06-0267 17202311
39. Singh B Reddy PG Goberdhan A Walsh C Dao S Ngai I Chou TC O-Charoenrat P Levine AJ Rao PH Stoffel A p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas Genes Dev 2002, 16:984-993. 152354 11959846 10.1101/gad.973602
40. Chan WY Cheung KK Schorge JO Huang LW Welch WR Bell DA Berkowitz RS Mok SC Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers Am J Pathol 2000, 156:409-417. 1850061 10666369
41. Kohler MF Marks JR Wiseman RW Jacobs IJ Davidoff AM Clarke-Pearson DL Soper JT Bast RC Jr Berchuck A Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer J Natl Cancer Inst 1993, 85:1513-1519. 10.1093/jnci/85.18.1513 8360934
42. Wen WH Reles A Runnebaum IB Sullivan-Halley J Bernstein L Jones LA Felix JC Kreienberg R el-Naggar A Press MF p53 mutations and expression in ovarian cancers: Correlation with overall survival Int J Gynecol Pathol 1999, 18:29-41. 9891239
43. Singer G Oldt R 3rd Cohen Y Wang BG Sidransky D Kurman RJ Shih IeM Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 2003, 95:484-6. 12644542
44. Davies H Bignell GR Cox C Stephens P Edkins S Clegg S Teague J Woffendin H Garnett MJ Bottomley W Davis N Dicks E Mutations of the BRAF gene in human cancer Nature 2002, 417:949-54. 10.1038/nature00766 12068308
45. Kim JS Lee C Foxworth A Waldman T B-Raf is dispensable for KRAS-mediated oncogenesis in human cancer cells Cancer Res 2004, 64:1932-7. 10.1158/ 0008-5472.CAN-03-3862 15026326
46. Rajagopalan H Bardelli A Lengauer C Kinzler KW Vogelstein B Velculescu VE Tumorigenesis: RAF/KRAS oncogenes and mismatch-repair status Nature 2002, 418:934. 10.1038/418934a 12198537